ERBB2 and breast carcinoma: In the adjuvant setting, high densities of TILs and TLS have also been demonstrated to confer favorable response to chemotherapy in bladder cancer (20) and to trastuzumab in hormone receptor-negative, HER2+ breast cancer (55).